



NGL Fine-Chem Limited

Regd. Office : 301, E - Square, Subhash Road, Vile Parle East, Mumbai 400057, Maharashtra, INDIA.
Tel.: 022-40842222, 26108030, Email : info@nglfinechem.com, CIN : L24110MH1981PLC025884, Website : www.nglfinechem.com

August 10, 2022

To,
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai — 400 001.

To,
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No.C/1, G Block,
Bandra Kurla Complex, Bandra East, Mumbai 400050.

Sub: Resubmission of Unaudited Financial Results for the quarter ended June 30, 2022.
Scrip Code: 524774 Symbol: NGLFINE

Dear Sir/Madam,

With reference to the submission of the Unaudited Financial Results of the Company for the quarter ended June 30, 2022, we would like to inform you that due to inadvertent typographical error in the Gain/(Loss) on actuarial valuation of post-employment benefits under Other Comprehensive Income column, the figure mentioned is (9.47) instead of (9.65).

We hereby resubmit the Unaudited Financial Results for the quarter ended on June 30, 2022.

We apologies for the inconvenience caused to you and request you to update the same in your records,

Thanking you,

Yours faithfully,
For NGL Fine-Chem Limited

Pallavi Pednekar
Company Secretary & Compliance Officer
Membership No: A33498



Encl: As Above.

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2022

Rupees in lakhs

Rupees in lakhs

	Particulars	Quarter ended		Year ended	
		30.06.2022 (Unaudited)	31.03.2022 (Audited)		30.06.2021 (Unaudited)
I	Revenue from Operations	6,460.96	8,406.38	31,750.30	31,866.74
II	Other Income	314.13	297.64	1,068.25	1,263.99
III	Total Revenue (I+II)	6,775.09	8,704.02	32,818.55	33,130.73
IV	Expenses :				
a)	Cost of Material Consumed	3,099.29	4,898.57	16,967.13	17,034.64
b)	(Increase)/Decrease in stock in trade and work in progress	426.15	(905.47)	(2,268.02)	(2,203.14)
c)	Employee benefits expenses	889.98	927.06	3,485.27	3,305.04
d)	Finance Costs	49.80	153.51	156.16	156.16
e)	Depreciation and amortisation expenses	360.49	347.68	1,036.90	767.31
f)	Other expenses	1,896.29	2,429.86	6,781.47	7,173.32
	Total Expenses (IV)	6,721.00	7,851.21	26,158.91	26,233.33
V	Profit/(loss) before exceptional items and tax (III-IV)	54.09	852.81	6,659.63	6,897.40
VI	Exceptional Items	-	-	-	-
VII	Profit/(loss) Before Tax (V-VI)	54.09	852.81	6,659.63	6,897.40
VIII	Tax Expense				
a)	Current Tax	(87.50)	(295.50)	(605.50)	(600.00)
b)	MAT Tax	-	-	-	-
c)	Prior Years	-	-	-	-
d)	Deferred Tax	85.18	129.41	(38.82)	(39.69)
	Profit (Loss) for the period from continuing operations (VII-VIII)	51.77	686.72	1,912.58	1,934.87
IX	Other Comprehensive Income				
a)	Gain/(Loss) on actuarial valuation of post employment benefits	(9.65)	8.54	2.10	2.12
b)	Deferred tax on above	2.39	(2.15)	(0.53)	(0.54)
c)	Other Comprehensive Income (Net of Tax)	(7.26)	6.39	1.57	1.58
	Total Comprehensive Income	44.51	693.11	1,914.15	1,936.45
XII	Paid-up Equity Share Capital (Face Value of the Share Rs. 5/- each)	308.90	308.90	308.90	308.90
XXIII	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	N.A	N.A	N.A	N.A
XIV	Earnings Per Share (EPS)				
a)	Basic	₹ 0.84	₹ 11.12	₹ 30.96	₹ 31.32
b)	Diluted	₹ 0.84	₹ 11.12	₹ 30.96	₹ 31.32

Notes:

- The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Wednesday, 10th Aug, 2022. These results were subjected to Limited Review by the Statutory Auditors of the Company.
- The Company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS 108 "Operating Segment" notified pursuant to Companies (Indian Accounting Standards) Rule 2015.
- The consolidated results are for NGL Fine Chem Limited together with its 100% subsidiary Macrotech Polyochem Private Limited.
- Previous period figures have been regrouped/rearranged wherever necessary.

Notes:

- The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Wednesday, 10th Aug, 2022. These results were subjected to Limited Review by the Statutory Auditors of the Company.
- The Company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS 108 "Operating Segment" notified pursuant to Companies (Indian Accounting Standards) Rule 2015.
- Previous period figures have been regrouped/rearranged wherever necessary.